Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.59 |
| ▸ | FAAH | O00519 | 11/20 | 0.48 |
| ▸ | CES1 | P23141 | 10/20 | 0.48 |
| ▸ | CES2 | O00748 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octane SCHEMBL8472525 | 1.00 | EPHX1 (0.59) | EPHX1FAAHCES1CES2MEN1 | |
| Decane SCHEMBL27619136 | 1.00 | EPHX1 (0.59) | EPHX1FAAHCES1CES2MEN1 | |
| Trifluoromethanesulfonic Acid SCHEMBL31222713 | 1.00 | EPHX1 (0.59) | EPHX1FAAHCES1CES2MEN1 | |
| Trifluoromethanesulfonic Acid SCHEMBL3129636 | 0.97 | EPHX1 (0.56) | EPHX1FAAHCES1CES2MEN1 | |
| Trifluoromethanesulfonic Acid SCHEMBL6544414 | 0.89 | EPHX1 (0.50) | EPHX1FAAHCES1CES2MEN1 | |
| Octadecylamine SCHEMBL6930485 | 0.89 | DNM1 (0.54) | EPHX1FAAHCES1CES2MEN1 | |
| Trifluoromethanesulfonic Acid SCHEMBL28345163 | 0.89 | EPHX1 (0.50) | EPHX1FAAHCES1CES2MEN1 | |
| Trifluoromethanesulfonic Acid SCHEMBL2857301 | 0.89 | SLC22A1 (0.54) | EPHX1CES1HSD17B10 | |
| Tetrahexylammonium SCHEMBL2862383 | 0.89 | SLC22A1 (0.54) | EPHX1CES1HSD17B10 | |
| Trifluoromethanesulfonic Acid SCHEMBL2550111 | 0.87 | EPHX1 (0.48) | EPHX1FAAHCES1CES2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116253606-A | Preparation method of aryl difluoromethyl alkyl sulfonyl fluoride compound | 上海应用技术大学 | 2023-06-13 | — | — | CN | claimed |
| CN-113698325-A | Method for preparing alkyl sulfonyl fluoride | 上海应用技术大学 | 2021-11-26 | — | — | CN | claimed |
| US-12234203-B2 | Process for the synthesis of cannabidiol and intermediates thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2025-02-25 | — | — | US | disclosed |
| CN-116253606-A | Preparation method of aryl difluoromethyl alkyl sulfonyl fluoride compound | 上海应用技术大学 | 2023-06-13 | — | — | CN | disclosed |
| CN-113698325-B | Method for preparing alkyl sulfonyl fluoride | 上海应用技术大学 | 2022-12-16 | — | — | CN | disclosed |
| US-20220340507-A1 | PROCESS FOR THE SYNTHESIS OF CANNABIDIOL AND INTERMEDIATES THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2022-10-27 | — | — | US | disclosed |
| CN-113698325-A | Method for preparing alkyl sulfonyl fluoride | 上海应用技术大学 | 2021-11-26 | — | — | CN | disclosed |
| CN-102482238-B | Conjugates, process for their preparation and their therapeutic use | SAI NUOFEI (FR) | 2015-08-12 | — | — | CN | disclosed |
| CN-101228131-B | Novel heterocyclylideneacetamide derivatives | MOCHIDA PHARM CO LTD | 2013-01-09 | — | — | CN | disclosed |
| CN-102482238-A | Novel conjugates, process for their preparation and their therapeutic use | SANOFI AVENTIS | 2012-05-30 | — | — | CN | disclosed |
| CN-101228131-A | Novel heterocyclylideneacetamide derivatives | MOCHIDA PHARM CO LTD (JP) | 2008-07-23 | — | — | CN | disclosed |
| EP-1089729-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999066927-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999065492-A1 | INHIBITION OF SEROTONIN REUPTAKE | ELI LILLY AND COMPANY (US) | 1999-12-23 | — | — | WO | disclosed |
| CN-1222912-A | Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment | MERCK & CO INC (US) | 1999-07-14 | — | — | CN | disclosed |
| US-5892035-A | FLUORINATING THE CORRESPONDING DIAZABICYCLOALKALINE COMPOUND | DAIKIN INDUSTRIES LTD. (JP) | 1999-04-06 | — | — | US | disclosed |
| US-5756725-A | CARBAPENEM NUCLEUS IS SUBSTITUTED AT THE 2-POSITION WITH A NAPHTHOSULTAM LINKED THROUGH A CH2 GROUP | MERCK & CO., INC. (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0750620-A4 | CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0750620-A1 | CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO. INC. (US) | 1997-01-02 | — | — | EP | disclosed |
| WO-1995025108-A1 | CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 1995-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234203-B2 | Process for the synthesis of cannabidiol and intermediates thereof | CNR2, CNR1, MCCC2 | EPHX1 698/4885FAAH 11/4885CES1 508/4885 |
| US-20220340507-A1 | PROCESS FOR THE SYNTHESIS OF CANNABIDIOL AND INTERMEDIATES THEREOF | CNR2, CNR1, MCCC2 | EPHX1 698/4885FAAH 11/4885CES1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.